The beneficial effects of FXR activation by 6-ethyl-chenodeoxycholic acid (obeticholic acid: OCA), a potent activator of FXR, have been reported in rats with diabetes mellitus, obesity, insulin resistance, and liver steatosis. Here, NR1H4 is linked to fatty liver disease.